De la Cruz Ku Gabriel, Desai Anshumi, Hickey Alanna, Valcarcel Bryan, Wareham Carly, Hernandez Alexandra, Arias-Rivera Eva Esperanza, Chambergo-Michilot Diego, Linshaw David, Ziegler-Rodriguez Gonzalo, Persing Sarah M, Homsy Christopher, Chatterjee Abhishek, Nardello Salvatore M
Universidad Científica del Sur, Lima, Peru.
Division of Plastic and Reconstructive Surgery, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
J Surg Oncol. 2025 Jun;131(7):1258-1271. doi: 10.1002/jso.28088. Epub 2025 Jan 13.
Triple-negative breast cancer (TNBC) has a prevalence of 12%-24% in the Hispanic population. Previous research has demonstrated that disparities in healthcare access significantly influence patient outcomes. We aimed to compare the clinicopathological characteristics and outcomes of Hispanic females with TNBC living in Latin America (HPLA) to the Hispanic population in the United States (HPUS).
We evaluated two retrospective cohorts: patients diagnosed with TNBC at the Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru, during 2000-2015, and HPUS patients with TNBC from the Surveillance, Epidemiology, and End Results Program (SEER).
A total of 2007 HPLA and 8457 HPUS patients were included. The HPLA patients were younger and more frequently lived in nonmetropolitan areas. HPLA had higher T and N (p < 0.001) stages. HPLA patients were more likely to present with Stage III disease (51.6% vs. 20.8%), while Stage IV presentations were similar 6.6% vs. 6.8%. HPLA patients with Stages I and II more frequently underwent mastectomy compared to HPUS (56.2 vs. 48.0%). HPLA patients received neoadjuvant chemotherapy (p < 0.001), adjuvant chemotherapy (p < 0.001), and radiotherapy (p < 0.001) more often. While early breast cancer stages had similar overall survival (OS) rates for both populations, HPLA patients had worse 5-year OS rates compared to HPUS patients in Stages III (39.9% vs. 52.3%, p < 0.001) and IV (4.6% vs. 10.7%, p < 0.001).
Hispanic females living in Latin America were more frequently diagnosed with advanced stages of TNBC and more often underwent mastectomy, even in early-stage disease. When analyzing advanced stages, HPLA had worse OS rates compared to HPUS.
三阴性乳腺癌（TNBC）在西班牙裔人群中的患病率为12%-24%。先前的研究表明，医疗保健可及性的差异会显著影响患者的治疗结果。我们旨在比较生活在拉丁美洲的西班牙裔女性三阴性乳腺癌患者（HPLA）与美国的西班牙裔人群（HPUS）的临床病理特征和治疗结果。
我们评估了两个回顾性队列：2000年至2015年期间在秘鲁利马国家肿瘤研究所被诊断为TNBC的患者，以及来自监测、流行病学和最终结果计划（SEER）的美国西班牙裔TNBC患者。
共纳入2007例HPLA患者和8457例HPUS患者。HPLA患者更年轻，且更常居住在非大都市地区。HPLA患者的T和N分期更高（p<0.001）。HPLA患者更有可能表现为III期疾病（51.6%对20.8%），而IV期表现相似（6.6%对6.8%）。与HPUS相比，I期和II期的HPLA患者更常接受乳房切除术（56.2%对48.0%）。HPLA患者更常接受新辅助化疗（p<0.001）、辅助化疗（p<0.001）和放疗（p<0.001）。虽然两个群体早期乳腺癌阶段的总生存率（OS）相似，但在III期（39.9%对52.3%，p<0.001）和IV期（4.6%对10.7%，p<0.001），HPLA患者的5年OS率低于HPUS患者。
生活在拉丁美洲的西班牙裔女性更常被诊断为TNBC晚期，且更常接受乳房切除术，即使是在早期疾病中。在分析晚期阶段时，HPLA患者的OS率低于HPUS患者。
